To date, the company has raised $29 million from investors including Concord Ventures (Israel), Reslo Life Sciences Ltd. (Israel), Alex Brown - Deutsche Bank (US), Giza Fund (GE Capital; Israel), The Challenge Fund (Etgar - Israel) and Teva Pharmaceutical Industries Ltd.

Investors:

Concord Ventures

The Challenge Fund

Giza Venture Fund

ABS ventures

Teva Pharmaceutical Industries Ltd.